- Biodesix Announces Initiation of Clinical Phase Biomarker Development Program with Merck KGaA, Darmstadt, Germany and Pfizer Inc.
- Biodesix Partners with Streck to Support In Vitro Diagnostic (IVD) Strategy
- AVEO Oncology and Biodesix Announce Results from Phase 1b Study of Ficlatuzumab, Gemcitabine and Nab-paclitaxel in Advanced Pancreatic Cancer
Incidental Lung Nodule Test
Designed to help identify likely benign lung nodules with a simple to use blood-based test.